Evidence mapPaperPMID 42201372Full record

Observational studyLung2026

Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry.

Sharashchandra Shetty, Aparna C Swaminathan, Peide Li, Megan L Neely, Amy L Olson, Laurie D Snyder, ILD-PRO Registry investigators

Registry-linked trialAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01915511 (Idiopathic Pulmonary Fibrosis Prospective Outcomes), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01915511 recruitingnot on this map

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry

Typeobservational_patient_registrySponsorDuke UniversityRan2014 to 2031Enrolled3,000ConditionsIdiopathic Pulmonary Fibrosis, Interstitial Lung Disease
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sharashchandra ShettyBoehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Rd, Ridgefield, CT, 06877, USA. sharashchandra.shetty@boehringer-ingelheim.com.
Aparna C SwaminathanDuke Clinical Research Institute, Durham, NC, USA.ORCID http://orcid.org/0000-0002-0003-9971
Peide LiBoehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Rd, Ridgefield, CT, 06877, USA.
Megan L NeelyDuke Clinical Research Institute, Durham, NC, USA.ORCID http://orcid.org/0000-0002-0101-1081
Amy L OlsonBoehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Rd, Ridgefield, CT, 06877, USA.ORCID http://orcid.org/0000-0002-5368-0412
Laurie D SnyderDuke Clinical Research Institute, Durham, NC, USA.ORCID http://orcid.org/0000-0002-5962-2184
ILD-PRO Registry investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePulmonary fibrosis may impair an individual's ability to work. We assessed the extent, cost and factors associated with workplace productivity loss among patients with progressive pulmonary fibrosis (PPF).

methodsThe multi-center ILD-PRO Registry enrolled US patients with progressive interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis. Workplace productivity loss was assessed using the Work Productivity and Activity Impairment (WPAI) questionnaire. Associations between patient characteristics and workplace productivity loss among employed patients were analyzed using logistic regression.

resultsAmong 175 employed patients of 597 who completed the WPAI questionnaire, 58.3% were female, median age was 58 years, median forced vital capacity (FVC) was 58.7% predicted; 20.0% used oxygen with activity and at rest. In the past 7 days, mean (SD) hours worked was 32.9 (15.8) and mean (SD) working hours lost was 10 (12). Mean (SD) percentage of working hours lost was 24.4 (30.2). Mean (SD) working hours lost due to absenteeism and presenteeism were 4 (9) and 8 (11), respectively. Among patients with any productivity loss, the estimated mean (SD) annual cost of productivity loss was $24,815 ($17,917). Lower FVC % predicted, higher (worse) St. George's Respiratory Questionnaire scores and lower (worse) Cough and Sputum Assessment Questionnaire cough impact and symptoms scores were associated with greater odds of productivity loss.

conclusionsPatients with PPF showed significant impairment in workplace productivity. Worse lung function and worse scores on patient-reported outcomes were associated with a greater likelihood of productivity loss. Trial Registration ClinicalTrials.gov; No: NCT01915511; registered August 5, 2013; URL: www. CLINICALTRIALS: gov .

Indexed as

AbsenteeismEfficiencyPresenteeismPulmonary FibrosisWorkplaceAgedCost of IllnessDisease ProgressionFemaleHumansMaleMiddle AgedRegistriesSurveys and QuestionnairesUnited StatesVital CapacityAbsenteeismCost of illnessInterstitial lung diseasesObservational studyPresenteeism

Identifiers

PMID42201372
PMCPMC13319162

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.